[go: up one dir, main page]

PE20151888A1 - Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion - Google Patents

Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion

Info

Publication number
PE20151888A1
PE20151888A1 PE2015001552A PE2015001552A PE20151888A1 PE 20151888 A1 PE20151888 A1 PE 20151888A1 PE 2015001552 A PE2015001552 A PE 2015001552A PE 2015001552 A PE2015001552 A PE 2015001552A PE 20151888 A1 PE20151888 A1 PE 20151888A1
Authority
PE
Peru
Prior art keywords
methods
compositions
formula
depression
treat depression
Prior art date
Application number
PE2015001552A
Other languages
English (en)
Inventor
Argeris Karabelas
Lorenzo Pellegrini
Remy Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PE20151888A1 publication Critical patent/PE20151888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe composiciones y metodos para el tratamiento de la depresion, utilizando composiciones que comprenden compuestos de fenoxipropilamina de formula I y derivados que tienen afinidad selectiva para y actividad antagonista, en contra del receptor 5-HT1A, asi como la actividad inhibitoria de la recaptacion de 5-HT. Adicionalmente, se describe, las composiciones y metodos para tratar la depresion utilizando composiciones que comprenden un compuesto de la formula II. Tambien son descritos, metodos para el tratamiento o disminucion de a lo menos un sintoma de la depresion en un sujeto humano, con una composicion que comprende un compuesto de la formula (I) o formula (II), o una sal farmaceuticamente aceptable, hidrato, o solvato de la misma
PE2015001552A 2013-01-24 2014-01-24 Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion PE20151888A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756208P 2013-01-24 2013-01-24
US201361799482P 2013-03-15 2013-03-15
US201361852149P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151888A1 true PE20151888A1 (es) 2016-01-13

Family

ID=51208168

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001552A PE20151888A1 (es) 2013-01-24 2014-01-24 Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion

Country Status (23)

Country Link
US (3) US20140206722A1 (es)
EP (2) EP3925608A3 (es)
JP (2) JP6422890B2 (es)
KR (4) KR102247960B1 (es)
CN (2) CN110664813A (es)
AU (4) AU2014209200B2 (es)
BR (1) BR112015017628A2 (es)
CA (2) CA3150231A1 (es)
CL (1) CL2015002069A1 (es)
DK (1) DK2948143T3 (es)
ES (1) ES2875058T3 (es)
IL (4) IL287727B2 (es)
MX (2) MX2015009445A (es)
MY (1) MY185908A (es)
NZ (2) NZ750189A (es)
PE (1) PE20151888A1 (es)
PH (1) PH12015501643B1 (es)
PL (1) PL2948143T3 (es)
PT (1) PT2948143T (es)
RU (2) RU2020120236A (es)
SG (2) SG10201706035QA (es)
WO (1) WO2014117003A1 (es)
ZA (2) ZA201505114B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205399A1 (en) * 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
WO2019070939A1 (en) * 2017-10-04 2019-04-11 NeuroGeneces LLC SLEEP PERFORMANCE SYSTEM AND METHOD OF USE
GB2591937B (en) 2018-09-04 2023-06-07 Minerva Neurosciences Inc Methods of using a phenoxypropylamine compound to treat pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
EA004704B1 (ru) * 1999-05-24 2004-06-24 Мицубиси Фарма Корпорейшн Производные феноксипропиламина
DE60010758T2 (de) * 1999-12-20 2005-05-12 Eli Lilly And Co., Indianapolis Piperidin-derivate und ihre verwendung als serotonin rezeptor antagonisten
RU2424799C1 (ru) * 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте

Also Published As

Publication number Publication date
KR20150120987A (ko) 2015-10-28
PT2948143T (pt) 2021-06-03
KR102172351B1 (ko) 2020-11-02
PH12015501643A1 (en) 2015-10-12
IL239928B (en) 2021-04-29
ES2875058T3 (es) 2021-11-08
PH12015501643B1 (en) 2015-10-12
IL311363A (en) 2024-05-01
IL278109B (en) 2022-03-01
IL278109A (en) 2020-11-30
DK2948143T3 (da) 2021-07-26
EP2948143A4 (en) 2017-02-22
SG11201505737YA (en) 2015-08-28
SG10201706035QA (en) 2017-08-30
AU2022241458B2 (en) 2024-11-14
RU2020120236A (ru) 2020-09-01
CN105377255A (zh) 2016-03-02
ZA202207530B (en) 2023-10-25
CA2898279C (en) 2022-05-17
IL239928A0 (en) 2015-08-31
CN110664813A (zh) 2020-01-10
JP6422890B2 (ja) 2018-11-14
CA2898279A1 (en) 2014-07-31
MX388354B (es) 2025-03-19
US20200223838A1 (en) 2020-07-16
JP6657315B2 (ja) 2020-03-04
NZ709967A (en) 2020-05-29
JP2018172400A (ja) 2018-11-08
US20140206722A1 (en) 2014-07-24
RU2725112C2 (ru) 2020-06-29
KR102587177B1 (ko) 2023-10-06
KR20200086377A (ko) 2020-07-16
IL287727B1 (en) 2024-04-01
EP2948143B1 (en) 2021-05-05
AU2022241458A1 (en) 2022-10-20
KR20220112865A (ko) 2022-08-11
EP2948143A1 (en) 2015-12-02
AU2019200512A1 (en) 2019-02-14
RU2015135358A (ru) 2017-03-03
IL287727B2 (en) 2024-08-01
WO2014117003A1 (en) 2014-07-31
BR112015017628A2 (pt) 2017-07-11
CA3150231A1 (en) 2014-07-31
AU2014209200A1 (en) 2015-07-30
KR20210047368A (ko) 2021-04-29
AU2020205268B2 (en) 2022-07-07
KR102247960B1 (ko) 2021-05-07
EP3925608A3 (en) 2022-01-19
MX2015009445A (es) 2016-01-14
JP2016510331A (ja) 2016-04-07
AU2014209200B2 (en) 2018-11-01
PL2948143T3 (pl) 2021-12-13
IL287727A (en) 2021-12-01
EP3925608A2 (en) 2021-12-22
NZ750189A (en) 2020-08-28
CL2015002069A1 (es) 2016-05-20
AU2019200512B2 (en) 2020-04-16
MY185908A (en) 2021-06-14
US20250109127A1 (en) 2025-04-03
ZA201505114B (en) 2023-09-27
AU2020205268A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
NI201700135A (es) Derivados de ciclohexano sustituido con amido
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
HN2011000629A (es) Derivados de picolinamida como inhibidores de cinasa
CU20130033A7 (es) Imidazopiridazinas sustituidas
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
BR112017006113A2 (pt) combinações sinérgicas de auristatina
MX2015014181A (es) 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
NI201500118A (es) Imidazopiridazinas sustituidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
NI201700078A (es) Pirazolpiridinaminas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CR20160042A (es) ANTAGONISTAS DE V1a PARA TRATAR TRASTORNOS DEL SUEÑO POR CAMBIO DE FASE
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
PE20151888A1 (es) Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion
MX378190B (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2023006909A (es) Metodos de uso de compuestos de fenoxipropilamina para tratar la depresion.
TH158821A (th) วิธีการของการใช้งานของสารประกอบฟีนอกซีโพรพิลเอมีน เพื่อบำบัดภาวะซึมเศร้า
AR094934A1 (es) Imidazopiridazinas sustituidas

Legal Events

Date Code Title Description
FC Refusal